Videos and podcasts

Listen to Associate Professor Karthik Ramasamy discuss the real-world evidence from the INSURE study, exploring whether some patients could benefit from retreatment with LEN or proteasome inhibitors during their treatment of RRMM.^1,2

Associate Professor Ramasamy also presents a case study of a patient with relapsed MM.

If you would like to discuss this content with a Takeda representative, please click here. 

Listen to Professor Julia Scarisbrick, Consultant Dermatologist at University Hospital Birmingham NHS Foundation Trust, and Dr Wendy Osborne, Consultant Haematologist at Newcastle Hospitals NHS Foundation Trust, discuss the multidisciplinary management of adult patients with CTCL. They explore the role of haematologists, dermatologists, oncologists and clinical nurse specialists in managing these patients. 

Listen to clinical experts explore the heterogeneous nature of CTCL, defining the subtypes MF, pcALCL and SS. Professor Whittaker, Consultant Dermatologist at Guy’s and St. Thomas’ NHS Foundation Trust, and   

Listen to Dr Matthew Wilson, Consultant Haematologist at the Beatson West of Scotland Cancer Centre, and Dr Wendy Osborne, Consultant Haematologist at Newcastle Hospitals NHS Foundation Trust, discuss diverse clinical presentations of sALCL and their personal management strategies by exploring two real-world patient case studies. 

Listen to Dr Sharmistha Ghosh discuss the management of cardiac adverse events, including bradycardia and hypertension, which may be experienced in patients with ALK+ aNSCLC who take ALUNBRIG.

Dr Ghosh explains the recommended dose modifications for ALUNBRIG in cases of bradycardia and hypertension, as well as her clinical experience of managing these adverse events.

Listen to Dr Yvonne Summers provide her opinion on pill burden and the convenience of once daily dosing during treatment with ALUNBRIG for ALK+ aNSCLC.

ALK+, anaplastic lymphoma kinase positive; aNSCLC, advanced non-small cell lung cancer. 

Listen to Dr Sharmistha Ghosh discuss the management of skin toxicities which may occur in patients with ALK+ aNSCLC who take ALUNBRIG.

Dr Ghosh explains the recommended dose modifications for ALUNBRIG if patients experience skin toxicities as well as the guidance relating to photosensitivity and photodermatosis.

ALK+, anaplastic lymphoma kinase positive; aNSCLC, advanced non-small cell lung cancer.

Listen to Prof Samreen Ahmed highlight the impact of brain metastases on quality of life in patients with ALK+ aNSCLC and why intracranial monitoring and management is important in these patients. 

Prof Ahmed reviews ALUNBRIG’s intracranial efficacy vs crizotinib in patients with ALK+ aNSCLC from the pivotal ALTA-1L trial and discusses why ALUNBRIG could be a suitable treatment option in patients with ALK+ aNSCLC.

Listen to Dr Sharmistha Ghosh provide an overview of the results from the ALTA-1L retrospective chart review study which provides insight into the use of subsequent systemic anticancer treatments in patients with ALK+ aNSCLC following discontinuation of 1L ALUNBRIG from the ALTA-1L trial. 

Dr Ghosh discusses specific data relating to lorlatinib, as the most commonly used 2L ALK TKI used within the retrospective chart review, and as a licensed treatment option after progression on 1L ALUNBRIG in Great Britain.

Listen to Prof Samreen Ahmed review ALUNBRIG’s systemic efficacy from the ALTA-1L trial which compared first-line use of ALUNBRIG vs crizotinib in patients with ALK+ aNSCLC. 

Using a real-world example from the ALTA-1L study, Prof Ahmed highlights the importance of ALUNBRIG as a first-line treatment option in improving symptoms of patients with ALK+ aNSCLC. 

Listen to Prof Samreen Ahmed explore the funded ALK TKI treatment options available for ALK+ aNSCLC in England as per NICE TA, CDF and NHS England Blueteq eligibility criteria. 

Listen to Dr Yvonne Summers discuss the current unmet needs of patients with ALK+ aNSCLC, including the negative impact of brain metastases on the daily lives of these patients. 

Dr Summers provides an overview of the ALUNBRIG health-related QOL data from the ALTA-1L study in patients with ALK+ aNSCLC and how these results compare with her real-world experience in clinical practice.